Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts.
C Capelli, M Domenghini, G Borleri...
https://pubmed.ncbi.nlm.nih.gov/17680021/Actively Recruiting
Led by Regenexx, LLC · Updated on 2025-04-06
42
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating two platelet-based treatments spaced four weeks apart compared to sham procedures for treating painful lumbar degenerative disc disease. This single-blind, randomized, placebo-controlled study aims to observe improvements in patient-reported outcomes from baseline to three months after the second treatment, with ongoing assessment of effectiveness and durability up to twelve months. The study includes adults aged 25 to 65 years with confirmed degenerative disc disease who have not responded to prior conservative treatments. Participants receive either two treatments involving platelet-rich plasma, platelet lysate, and platelet poor plasma injections into specific areas of the lumbar spine or two sham procedures mimicking the treatment without injecting any substances. The treatments involve drawing and processing the patients blood, followed by ultrasound or x-ray guided injections into the multifidus muscle, epidural space, facet joints, tendon insertions, and ligaments at the affected spinal levels. The sham group undergoes needle placements without injections. After three months, patients in the sham group may crossover to receive the real treatment and continue follow-up accordingly. Participants attend a pretreatment visit at or before enrollment, with follow-up visits at three and twelve months post-injection. They complete questionnaires assessing pain and function at one, three, six, and twelve months. Researchers measure outcomes including pain scales, functional indexes, disability scores, medication use, adverse events, and additional treatments. The total participation lasts up to one year with ongoing monitoring of clinical outcomes and safety throughout the study period.
CONDITIONS
Trial for Treating Painful Degenerative Disc Disease
E
Ehren Dodson, PhD
N
Neven Steinmetz, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Regenexx, LLC
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Platelet-Based Spine Injections (PRP, PL, PPP) | Sham Procedure | Lumbar Fusion Surgery (Current-care Comparator) |
|---|---|---|---|
| What it is | Injections using autologous platelet-rich plasma (PRP), platelet lysate (PL), and platelet-poor plasma (PPP) prepared from the patient’s own blood and delivered to multiple spine and ligament sites under guidance. | A control procedure in which needles are inserted to mimic injections at the same locations while under sedation, but no active treatment is delivered. | Surgical fusion permanently joins two or more vertebrae, stabilizing the spine by removing the degenerated disc and using hardware or bone grafts, typically for cases of pain and instability not responding to less invasive therapies. |
| Role in trial | Investigational intervention evaluated for its effect on pain and function in chronic painful lumbar degenerative disc disease. | Control procedure to distinguish true effect of injections from placebo and participant expectations. | Included for external clinical context as the common next-step standard of care following failed non-surgical interventions; not evaluated within this trial. |
| Primary use | To evaluate if biological injections can improve pain and function for adults with chronic lumbar disc-related pain that has not responded to conservative therapies. | To provide a blinded control for outcome comparison and isolate the true effect of platelet-based injections. | Used in practice to relieve pain, restore function, and stabilize the spine in patients failing conservative and injection-based therapies for degenerative disc disease. |
| How it is given or performed | Patient’s blood is processed to derive PRP, PL, and PPP. These products are injected by a physician, using ultrasound or X-ray guidance, at multiple specific spine and ligament locations with sedation. | Needles are placed to simulate the real procedure in the same back areas but without injecting platelet preparations or any active substance. | Surgical procedure—performed under anesthesia—where discs are removed and vertebrae are fused with bone grafts and hardware for permanent stabilization. |
| Evidence status | Evidence for platelet-based injections in lumbar disc disease is promising but not yet conclusive. Early studies suggest possible improvements in pain and function for some patients, but large definitive trials are still ongoing. | Serves as the inactive control with no expected direct benefit beyond placebo; efficacy is not measured as a treatment. | Lumbar fusion is supported by decades of clinical use and remains a frequently used surgical approach, though its benefit for chronic pain (without instability) remains debated and patient selection is important. |
| Important limitations | Limited number of rigorous head-to-head studies with standard surgical interventions, with ongoing research needed to determine long-term outcomes and optimal patient selection. | Sham arms do not address long-term outcomes, side effect profiles, or comparisons to established surgical options. | Surgery carries risks such as infection, bleeding, hardware complications, and may result in incomplete pain relief or functional limitation. Outcomes are variable and not all patients benefit. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks between two treatments
Participants receive a series of two treatments spaced 4 weeks apart. The treatment involves guided injections of platelet-rich plasma, platelet lysate, and platelet poor plasma into specific areas of the lower back to treat painful degenerative disc disease. Participants in the sham group receive procedures mimicking treatment without actual injections.
2 visits (in-person) for treatments
Duration - Up to 12 months after treatment
Participants complete follow-up visits to assess pain and function at 3 and 12 months after treatment. Those in the sham group can crossover to receive the treatment after the 3-month follow-up and then follow the treatment group timeline from their second treatment.
2 visits (in-person) at 3 and 12 months post-treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
C Capelli, M Domenghini, G Borleri...
https://pubmed.ncbi.nlm.nih.gov/17680021/Laxmaiah Manchikanti, Vijay Singh, Frank J E Falco...
https://pubmed.ncbi.nlm.nih.gov/20648203/Vijay M Ravindra, Steven S Senglaub, Abbas Rattani...
https://pubmed.ncbi.nlm.nih.gov/30560029/Christopher Williams, Mairin Jerome, Chaz Fausel...
https://pubmed.ncbi.nlm.nih.gov/34659923/Silvia V Rodrigues, Anirudh B Acharya, Srinath L Thakur
https://pubmed.ncbi.nlm.nih.gov/22474794/Frank M Phillips, Paul J Slosar, Jim A Youssef...
https://pubmed.ncbi.nlm.nih.gov/23334400/Christopher J Centeno, John R Schultz, Michelle Cheever...
https://pubmed.ncbi.nlm.nih.gov/22023622/Christopher Centeno, Jason Markle, Ehren Dodson...
https://pubmed.ncbi.nlm.nih.gov/29177632/Regenexx, LLC
Lead Sponsor